Skip to content

Validation of a Remote Wireless Sensor Network (WSN) Approach to the Individualized Detection of Cocaine Use in Humans

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02018263
Enrollment
5
Registered
2013-12-23
Start date
2013-10-31
Completion date
2014-06-30
Last updated
2023-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cocaine Dependence

Brief summary

This study looks to explore the feasibility, sensitivity, validity, and specificity of a Remote Wireless Sensor Network (RWSN) approach to the detection of cocaine use/intoxication in the inpatient human laboratory, as well as in the outpatient setting (real world). Lastly, we look to design an algorithm for reliably detecting cocaine use in real-world settings and inference techniques for understanding the relationship between cocaine use and user contexts.

Interventions

BEHAVIORALExercise
DRUGNicotine

Sponsors

Yale University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

1. age 18 - 50 years, 2. voluntary, written, informed consent, 3. physically healthy by medical history, physical, neurological, ECG, and laboratory examinations, 4. DSM-IV criteria for Cocaine Abuse (305.60) or Cocaine Dependence (304.20) 5. recent street cocaine use in excess of amounts to be administered in the current study, 6. intravenous and/or smoked (crack/ freebase) use, 7. positive urine toxicology screen for cocaine, 8. for females, non-lactating, no longer of child-bearing potential (or agree to practice effective contraception during the study), and a negative serum pregnancy (β-HCG) test.

Exclusion criteria

1. Other drug dependence (except nicotine) as determined by urine toxicology or interview 2. \< 1 year of cocaine dependence, 3. a primary major DSM-IV psychiatric diagnosis (schizophrenia, bipolar disorder, etc.), unrelated to cocaine, 4. a history of significant medical (cardiovascular) or neurological illness, ie prior myocardial infarction, current active symptoms of cardiovascular disease / angina, evidence of cocaine-related cardiovascular symptoms, prior arrhythmias or need for cardiov ascular resuscitation, neurovascular events such as transient ischemic attacks, stroke, and/or seizures Parameters re: elevations in vital signs are now explicitly specified under Safety features built into our one-day self-administration paradigm). 5. current use of psychotropic and/or potentially psychoactive prescription medication, 6. seeking treatment for drug abuse/dependence (for experimental cocaine component), 7. physical or laboratory (β-HCG) evidence of pregnancy. 8. current use of any medication (prescription or over-the-counter) determined to cause potential drug interactions by the study physicians.

Design outcomes

Primary

MeasureTime frame
Instantaneous Heart Rate and Heart Rate Variability4 weeks

Secondary

MeasureTime frame
Instantaneous Respiration Rate4 Weeks
Hand-based/Foot-based Skin Conductance4 Weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026